An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment.

Trial Profile

An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Advanced breast cancer; Cancer; Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Thyroid cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 Aug 2014 Planned End Date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
    • 04 Aug 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top